CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 263 enrolled
Drug / intervention
Insulin Lispro +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00985712
NCT00985712Phase 4Completed
CompareCT.gov

A Randomized, Open-label Study on the Effects of Insulin Pen Devices on Glycemic Control in Children, Adolescents and Adults With Type 1 Diabetes: Novel Pen With Memory Function (HumaPen Memoir) vs. Conventional Pen Without Memory Function (HumaPen Luxura)

Eli Lilly and Company·interventional·Posted Sep 28, 2009·Updated Jun 4, 2012

In Brief

A Phase 4 clinical trial evaluating Insulin Lispro, Huminsulin Regular, and 2 other interventions for Diabetes Mellitus, Type 1. Completed, enrolled 263 participants across 29 sites.

Detailed Summary

The purpose of this study is to test the hypothesis that the HumaPen Memoir with memory function, when used over 24 weeks for prandial insulin injections achieves superior glycemic control, when compared to the conventional HumaPen Luxura without memory function.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 1
CountriesGermany
Collaborators--

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 28, 2009
Enrollment StartOct 1, 2009
Primary CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 16.8 years ago

Interventions

Insulin Lisprodrug

subcutaneously, daily (as determined by patient's blood glucose), for 24 weeks

Huminsulin Regulardrug

subcutaneously, daily (as determined by patient's blood glucose), for 24 weeks

HumaPen Memoirdevice

subcutaneously, daily for 24 weeks

HumaPen Luxuradevice

subcutaneously, daily for 24 weeks